Associations between corticosteroid dosage and clinical outcomes in patients with hypoxemic COVID-19 pneumonia: A retrospective cohort study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0308069 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Napassorn Teeratakulpisarn und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Hospital Mortality, COVID-19 Drug Treatment, Dexamethasone, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Corticosteroids are commonly used to treat COVID-19 patients with hypoxemia, and clinicians have adjusted the corticosteroid intensity on the basis of clinical needs. However, neither the optimal dose nor the duration of treatment has been recommended.
Objective
To investigate whether cumulative doses of corticosteroids, measured as dexamethasone-equivalent doses over the first 14 days, impact outcomes in patients with COVID-19 pneumonia.
Methods
We conducted a retrospective cohort study of COVID-19 pneumonia patients admitted between April 1 st , 2020, and September 30 th , 2021. The study focused on the type and dose of corticosteroid administered during the initial 14 days, clinical outcomes, and complications. The primary outcome was in-hospital mortality.
Results
Among 271 patients, the mean cumulative dexamethasone-equivalent dose was 158 (119.9–197.25) mg in survivors and 185 (131.7–222.0) mg in nonsurvivors. Univariate analysis revealed that the cumulative dexamethasone-equivalent dose was a risk factor for in-hospital mortality. However, this association did not hold true in the multivariate analysis. After the cumulative dexamethasone-equivalent dose was categorized into quartiles, the moderate dosage (126.01–165.00 mg) in the second quartile was found to be associated with the lowest in-hospital mortality (16.2%). Higher cumulative dexamethasone-equivalent doses were associated with longer hospital and ICU stays and fewer ventilator-free days (p < 0.001). Doses exceeding 165 mg were associated with an increased risk of hospital-acquired infections (p < 0.001).
Conclusions
The cumulative dexamethasone-equivalent dose during the first 14 days is not associated with in-hospital mortality in hypoxemic COVID-19 patients. However, higher cumulative doses exceeding 165 mg are associated with an increased risk of in-hospital mortality and secondary hospital-acquired infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
ORCID-Profile: Napassorn Teeratakulpisarn, Ranistha Ratanarat
Zitieren
APA
Teeratakulpisarn, N., Chiewroongroj, S., Naorungroj, T., & Ratanarat, R. (2024). Associations between corticosteroid dosage and clinical outcomes in patients with hypoxemic COVID-19 pneumonia: A retrospective cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0308069
Vancouver
Teeratakulpisarn N, Chiewroongroj S, Naorungroj T, Ratanarat R. Associations between corticosteroid dosage and clinical outcomes in patients with hypoxemic COVID-19 pneumonia: A retrospective cohort study. PLOS ONE. 2024. doi:10.1371/journal.pone.0308069
BibTeX
@article{Teeratakulpisarn2024,
author = {Teeratakulpisarn, Napassorn and Chiewroongroj, Supattra and Naorungroj, Thummaporn and Ratanarat, Ranistha},
title = {Associations between corticosteroid dosage and clinical outcomes in patients with hypoxemic COVID-19 pneumonia: A retrospective cohort study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0308069}
}
EUVIMED